Table 4 Comparison of VEP measurements at baseline and after 3 months by patient group (ozone treated diabetic patients versus controls). Comparison of VEP measurements of ozone-treated diabetic patients both at baseline and after 3 months against values from individuals without diabetes
From: Efficacy of ozone therapy on visual evoked potentials in diabetic patients
VEP parameter | Timeline | Study arm | P-value* | Non-diabetic subjects | P-value** | |
|---|---|---|---|---|---|---|
Treatment | Control | |||||
P100 wave latency (ms) | Baseline | 108.33 ± 5.36 | 108.31 ± 5.29 | N.S | 98.83 ± 4.48 | < 0.001 |
At 3 months | 106.76 ± 5.27 | 108.43 ± 5.31 | 0.032 |  | < 0.001 | |
P100 amplitude (μV) | Baseline | 4.03 ± 1.89 | 4.02 ± 1.91 | N.S | 7.08 ± 2.08 | < 0.001 |
At 3 months | 4.05 ± 1.93 | 4.02 ± 1.90 | N.S |  | < 0.001 | |
HbA1C (%) | Baseline | 9.04 ± 1.46 | 8.96 ± 1.54 | N.S |  |  |
At 3 months | 8.69 ± 1.47 | 8.87 ± 1.63 | 0.041 |  |  | |